How did the reverse stock split affect the share numbers in this CDTX Form 4?

A footnote explains that all numbers of securities and prices in the report have been adjusted to reflect Cidara’s 1‑for‑20 reverse stock split that was effected on April 24, 2024 , so the share and price data are presented on a post‑split basis.

Cidara Therapeutics (CDTX) CEO corrects past insider stock reports

Q: What does Cidara Therapeutics (CDTX) CEO Jeffrey Stein report in this Form 4?

The filing shows updated reporting by President & CEO Jeffrey Stein , a director of Cidara Therapeutics, for past transactions in common stock dating back to 2016, including corrections to previously filed Form 4 reports and disclosure of gifts of shares to a trust and to his sons.

Q: What gifts of Cidara Therapeutics stock are disclosed for Jeffrey Stein?

The table includes a transaction on December 31, 2021 coded as a gift (Code G) , involving transfers of Cidara common stock to a trust and to a son . A related footnote describes a gift of securities by Stein to his sons, with one son described as economically dependent on him.

Q: Does Jeffrey Stein claim beneficial ownership of all gifted CDTX shares?

No. The disclosure states that Stein disclaims beneficial ownership of the shares held by his independent son and that the report should not be deemed an admission that he is the beneficial owner of those shares for purposes of Section 16 or for any other purpose.

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Cidara Therapeutics’ President & CEO Jeffrey Stein, a director of the company, filed an updated Form 4 covering historical transactions in Cidara common stock. The filing restates prior reports from 2016, 2017, 2020 and 2021 to correct how many shares were shown as beneficially owned by him and to reclassify certain purchases as made by a trust rather than directly by him. All share and price figures in the table have been adjusted for the company’s 1‑for‑20 reverse stock split effected on April 24, 2024.

The filing also reports a gift of common stock on December 31, 2021 from Stein to his sons, with shares held both by a trust and by a son. The disclosure notes that he disclaims beneficial ownership of the shares held by his independent son, and states that the report should not be taken as an admission that he is the beneficial owner of those shares for Section 16 or any other purpose.

Insider Trade Summary

Net Buyer: 4,262 shares ($339,040)

Net Buy 12 txns

Insider Stein Jeffrey

Role President & CEO

Bought 4,262 shs ($339K)

Type	Security	Shares	Price	Value
Gift	Common Stock	1,873	$0.00	--
Gift	Common Stock	937	$0.00	--
Other	Common Stock	658	$0.00	--
Other	Common Stock	2,500	$40.006	$100K
Purchase	Common Stock	2,500	$40.006	$100K
Other	Common Stock	367	$135.80	$50K
Purchase	Common Stock	367	$135.80	$50K
Other	Common Stock	750	$118.948	$89K
Purchase	Common Stock	750	$118.948	$89K
Other	Common Stock	645	$155.00	$100K
Purchase	Common Stock	645	$155.00	$100K
Other	Common Stock	270	$0.00	--

Holdings After Transaction: Common Stock — 67,498 shares (Indirect, By trust); Common Stock — 5,763 shares (Direct)

Footnotes (1)

Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person. The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust. Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares. This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

01/07/2026 - 08:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stein Jeffrey

(Last)

(First)

(Middle)

6310 NANCY RIDGE DRIVE

SUITE 101

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
05/23/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/23/2016		J⁽¹⁾		270⁽²⁾	D	⁽¹⁾	10,025	D
Common Stock	03/31/2017		J⁽³⁾		645⁽²⁾	D	$155⁽²⁾	9,380	D
Common Stock	03/31/2017		P⁽³⁾		645⁽²⁾	A	$155⁽²⁾	65,754	I	By trust
Common Stock	06/05/2017		J⁽⁴⁾		750⁽²⁾	D	$118.948⁽²⁾	8,630	D
Common Stock	06/05/2017		P⁽⁴⁾		750⁽²⁾	A	$118.948⁽²⁾	66,504	I	By trust
Common Stock	09/12/2017		J⁽⁵⁾		367⁽²⁾	D	$135.8⁽²⁾	8,263	D
Common Stock	09/12/2017		P⁽⁵⁾		367⁽²⁾	A	$135.8⁽²⁾	66,871	I	By trust
Common Stock	11/10/2020		J⁽⁶⁾		2,500⁽²⁾	D	$40.006⁽²⁾	5,763	D
Common Stock	11/10/2020		P⁽⁶⁾		2,500⁽²⁾	A	$40.006⁽²⁾	69,371	I	By trust
Common Stock	12/10/2020		J⁽⁷⁾		658⁽²⁾	D	$0	1,442	I	By son
Common Stock	12/31/2021		G⁽⁸⁾		1,873⁽²⁾	D	$0	67,498	I	By trust
Common Stock	12/31/2021		G⁽⁸⁾		937⁽²⁾	A	$0	2,379	I	By son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person.

2. The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.

3. Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

4. Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

5. Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

6. Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust.

7. Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares.

8. This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What does Cidara Therapeutics (CDTX) CEO Jeffrey Stein report in this Form 4?

The filing shows updated reporting by President & CEO Jeffrey Stein, a director of Cidara Therapeutics, for past transactions in common stock dating back to 2016, including corrections to previously filed Form 4 reports and disclosure of gifts of shares to a trust and to his sons.

Which earlier insider reports for CDTX are being corrected in this filing?

The explanations state that prior Form 4s originally filed on May 23, 2016, April 4, 2017, June 7, 2017, September 12, 2017, November 10, 2020 and March 19, 2021 contained errors in the amount of securities beneficially owned or in whether securities were purchased by Stein personally or by a trust.

What gifts of Cidara Therapeutics stock are disclosed for Jeffrey Stein?

The table includes a transaction on December 31, 2021 coded as a gift (Code G), involving transfers of Cidara common stock to a trust and to a son. A related footnote describes a gift of securities by Stein to his sons, with one son described as economically dependent on him.

Does Jeffrey Stein claim beneficial ownership of all gifted CDTX shares?

No. The disclosure states that Stein disclaims beneficial ownership of the shares held by his independent son and that the report should not be deemed an admission that he is the beneficial owner of those shares for purposes of Section 16 or for any other purpose.

How are trust‑held Cidara shares treated in this insider report?

Several historical transactions are corrected to show that Cidara common stock was purchased by a trust rather than by Stein directly, and the table identifies those holdings as indirect ownership "By trust" following the respective transactions.